Novo's earnings results Wednesday differ from Eli Lilly's, whose stock slid on slower-than-expected sales of weight loss ...

Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

CNBC’s Angelica Peebles and Novo Nordisk CEO Lars Fruergaard Jørgensen join 'Squawk Box' to discuss the company's quarterly earnings results, demand for Wegovy, drug pipeline outlook, Cagrisema ...

NYSE-listed shares of Novo Nordisk surged 4% on Wednesday morning after the Danish pharmaceutical giant posted ...

The U.S. Centers for Medicare and Medicaid Services has named Novo Nordisk’s Wegovy, Ozempic and Rybelsus as part of the ...

President Trump will continue to pursue the policy of Medicare pricing negotiation introduced by former President Biden's ...

For five years, insulin manufacturer Novo Nordisk agrees to cap out-of-pocket cost of its insulin treatments at $35 per month, and provide free insulin to the neediest Minnesotans.

As the next round of Medicare drug pricing negotiations get underway, experts predict President Trump may seek to weaken the program.

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

IMMvention and Novo Nordisk form a partnership to co-develop oral therapies for sickle cell disease, focusing on BACH1 ...

Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 ...